Related Experiment Video
Updated: Aug 12, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Ceftriaxone in treatment of serious infections. Meningitis
1University of Virginia, Charlottesville.
Abstract:
In many pediatric infectious disease programs, ceftriaxone or cefotaxime is now the preferred drug for bacterial meningitis caused by H. influenzae, meningococci, and pneumococci. Ceftriaxone reaches a high bactericidal titer in the cerebrospinal fluid and persists at the site of infection longer than any other beta-lactam antibiotic. Short-course, once-daily therapy with ceftriaxone requires more study; currently, many pediatricians administer the agent twice daily for suspected or proven meningitis. Given the association of sequelae with prolongation of positive CSF cultures, ceftriaxone's rapid bactericidal activity is an advantage, which may require an adjunctive agent to block the inflammatory response due to antibiotic-induced release of endotoxin and other cell wall components. As empiric therapy, ceftriaxone is effective in infants and children three months to 18 years old. It is not yet recommended in neonates, because of concerns about bilirubin displacement. Thus, infants up to three months of age should receive ampicillin plus cefotaxime. In adults, ceftriaxone is effective therapy for presumed bacterial meningitis but must be combined with ampicillin initially, since L. monocytogenes meningitis cannot be excluded in most cases until CSF culture results are available.
Insights
Ceftriaxone is a preferred antibiotic for bacterial meningitis in children over three months old due to its rapid killing of bacteria in cerebrospinal fluid. Further research is needed for once-daily dosing, and it is not recommended for newborns.
Area of Science:
- Infectious Diseases
- Pediatrics
- Pharmacology
Background:
- Ceftriaxone and cefotaxime are frequently used for pediatric bacterial meningitis.
- Ceftriaxone demonstrates rapid bactericidal activity and prolonged presence in cerebrospinal fluid.
- Current practice often involves twice-daily ceftriaxone administration, though once-daily dosing warrants further investigation.
Purpose of the Study:
- To evaluate the efficacy and optimal dosing of ceftriaxone in treating bacterial meningitis.
- To discuss the role of ceftriaxone in empiric therapy for pediatric meningitis.
- To highlight considerations for ceftriaxone use in different age groups and specific pathogens.
Main Methods:
- Review of current clinical practices and literature regarding ceftriaxone and cefotaxime use.
- Analysis of pharmacokinetic properties of ceftriaxone in cerebrospinal fluid.
- Discussion of treatment guidelines for bacterial meningitis based on age and suspected pathogens.
Main Results:
- Ceftriaxone shows high bactericidal titers and persistence in CSF, outperforming other beta-lactams.
- Rapid bactericidal activity is advantageous in preventing sequelae associated with prolonged positive CSF cultures.
- Empiric ceftriaxone is effective for infants and children aged three months to 18 years, but not recommended for neonates.
Conclusions:
- Ceftriaxone is a key agent for treating bacterial meningitis in children over three months old.
- Ampicillin plus cefotaxime is recommended for infants up to three months.
- In adults, ceftriaxone requires initial combination with ampicillin to cover potential Listeria monocytogenes infections.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Rocky Mountain Spotted Fever
Bacterial Meningitis
Cryptococcal Meningitis
Inhibitors of Bacterial DNA Synthesis
Bacterial Meningitis I: Introduction

